Real-Time proton beam tracking could sharpen cancer therapy
NCT ID NCT07450560
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where the beam delivers energy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
30 people
The number who actually took part.
- Started
-
Feb 2026
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with solid tumors scheduled to receive proton therapy, with measurable lesions;
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients with solid tumors scheduled to receive proton therapy, with measurable lesions; 2. Signed the informed consent form. Exclusion Criteria: 1. Patients with a history of radioactive seed implantation; 2. Patients who cannot understand the purpose of treatment or are unwilling/unable to sign the informed consent form;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Solid tumor are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Provincial Hospital
Hefei, Anhui, 230001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A single arm, open label, dose-escalation phase i and dose-expansion phase IIa clinical study to evaluate the feasibility, safety, and efficacy of allogeneic chimeric antigen receptor (CAR) Gamma-Delta t cells CAR001 in subjects with Relapsed/Refractory solid tumors
- Can an antidepressant calm Chemotherapy's nerve pain?
- A new imaging agent aims to make solid tumors visible on PET scans
- Can a radioactive antibody seek out and destroy Hard-to-Treat tumors?
- Can a platform trial match the right drug combo to each tumor?
- Can immune cell infusions help fight solid tumors?